Article thumbnail

Arterial and Venous Thrombosis in Cancer Patients

By Andrew D. Blann and Simon Dunmore


The most frequent ultimate cause of death is myocardial arrest. In many cases this is due to myocardial hypoxia, generally arising from failure of the coronary macro- and microcirculation to deliver enough oxygenated red cells to the cardiomyocytes. The principle reason for this is occlusive thrombosis, either by isolated circulating thrombi, or by rupture of upstream plaque. However, an additionally serious pathology causing potentially fatal stress to the heart is extra-cardiac disease, such as pulmonary hypertension. A primary cause of the latter is pulmonary embolus, considered to be a venous thromboembolism. Whilst the thrombotic scenario has for decades been the dominating paradigm in cardiovascular disease, these issues have, until recently, been infrequently considered in cancer. However, there is now a developing view that cancer is also a thrombotic disease, and notably a disease predominantly of the venous circulation, manifesting as deep vein thrombosis and pulmonary embolism. Indeed, for many, a venous thromboembolism is one of the first symptoms of a developing cancer. Furthermore, many of the standard chemotherapies in cancer are prothrombotic. Accordingly, thromboprophylaxis in cancer with heparins or oral anticoagulation (such as Warfarin), especially in high risk groups (such as those who are immobile and on high dose chemotherapy), may be an important therapy. The objective of this communication is to summarise current views on the epidemiology and pathophysiology of arterial and venous thrombosis in cancer

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1996). A .A m i r k h o s r a v i ,M .A l e x a n d e r ,K .M a ye ta l . ,“ T h ei m p o r -tance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow
  2. (2001). A .D .Blann,D .G u rney ,M.W ad ley ,D .Bar e f or d ,P .St one lak e
  3. (2004). a a s i ,W .P .M i e l i c k i ,S .G .G o r d o n ,a n dW .K o r t e , “Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies,”
  4. (2000). A comparison of the safety and efficacy of oral antiocoagulation for the treatment ofvenousthromboembolicdiseaseinpatientswith orwithoutmalignancy,”ThrombosisandHaemostasis,vol.84,
  5. (1997). a g u c h i ,E .C .G a b a z z a ,H .Y a s u i ,T .K o b a y a s h i
  6. (1983). a i n ,D .C .T a b o r ,a n dJ .C .E n g l e ,“ P l a s m aβ-thromboglobulin levels in lung cancer,”
  7. (1991). a m a m o t o ,S .N o g u c h i ,K .M i y a u c h ie ta l . ,“ C h a n g e s in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer,”
  8. (2008). a n g e r ,B .S p a t h ,K .H a u b o l de ta l . ,“ T i s s u ef a c t o rp r o -coagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation,”
  9. (1995). A reliable marker of endothelial cell dysfunction: does it exist?”
  10. (1976). A.F.Abrahamsen,“Plateletturnoverinmetastaticcancerand the effect of platelet aggregation inhibitors,”
  11. (2009). A.K.Kakkar,“Antithrombotic therapy andsurvival incancer patients,” Best Practice and Research: Clinical Haematology,
  12. (1997). Activated-protein-C resistance in cancer patients,”
  13. (2009). Aggressive chronic platelet inhibition with prasugrelandincreasedcancerrisks:revisingoralantiplatelet regimens?”
  14. (1976). Altered viscosity and yield stress in patients with abdominal malignancy: relationship to deep vein thrombosis,”
  15. (2007). American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment
  16. (1998). andN.Suttorp,“VEGFinduceshyperpermeability byadirect action on endothelial cells,”
  17. (1997). Antithrombotic strategies in patients with cancer,” Thrombosis and Haemostasis,
  18. (1992). Arterial occlusive disease in occult cancer,”
  19. (1995). Arterial thrombosisassociatedwith granulocytemacrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases,”
  20. (2001). Atherosclerosis: a cancer of the blood vessels?”
  21. (2000). B r o x t e r m a n
  22. (2001). B¨ uller, “The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis,” Thrombosis and Haemostasis,
  23. (2010). Belmans et al.,“Clinical outcome of coronary stenting after thoracic radiotherapy: a casecontrol study,”
  24. (2001). Biochemistry of cancer procoagulant,”
  25. (2003). Blann,“How a damaged blood vessel wallcontibutes to thrombosisandhypertension,” Pathophysiologyof Haemostasis and Thrombosis,
  26. (2006). Cancer and thrombosis: managing the risks and approaches to thromboprophylaxis,”
  27. (2009). Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo,”
  28. (1997). Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue,”
  29. (1938). Carcinoma and venous thrombosis: the f r e q u e n c yo fa s s o c i a t i o no fc a r c i n o m ai nt h eb o d yo ft a i lo f the pancreas with multiple venous thrombosis,”
  30. (2006). Cardiovascular disease in rheumatoid arthritis,”Current
  31. (1988). Changes in blood coagulation and fibrinolyis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications?”
  32. (1974). Changes in platelets of cancer patients,”
  33. (1990). Chemotherapy enhances endothelial cell reactivity to platelets,” Clinical and Experimental Metastasis,
  34. (1993). Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies,”
  35. (1991). Coagulation/fibrinolysis balance and lung cancer,”
  36. (2008). Common risk factors for both arterial and venous thrombosis,”
  37. (2001). Complications of hepatic artery infusion: a review of 4580 reported cases,”
  38. (1988). Cytokine-mediated activation of vascular endothelium,”
  39. (2000). Cytokines and hemostasis,”
  40. (1992). Ddimer and CA 125 levels in patients with ovarian cancer10 Cardiology Research and Practice duringantineoplastictherapy:prognosticsignificanceforthe success of anti- cancer treatment,” Cancer,v o l .6 9 ,n o .9 ,p p .
  41. (2010). Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer,”
  42. (1984). Detection of enhanced in vivo platelet α-granule release in different patient groups—comparison of β-thromboglobulin, platelet factor 4 and thrombospondin assays,” Thrombosis and Haemostasis,
  43. (2010). Differential changes in platelet
  44. (1991). Differential platelet proaggregating activity of three Burkitt’s lymphomaderived human cell lines,”
  45. (1994). Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolisminstageIVbreastcancer,”Lancet,vol.343,
  46. (2002). e l l y ,A .R u d d ,R .R .L e w i s ,a n dB .J .H u n t ,“ P l a s m a D-dimers in the diagnosis of venous thromboembolism,”
  47. (2005). Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro,”
  48. (1997). eL u c i a ,F .D eV i t a ,M .O r d i t u r ae ta l . ,“ H yp e r c o a g u l a b l e state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein
  49. (2003). Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor,”
  50. (1986). Elevated plasma levels of betathromboglobulin in breast cancer,”
  51. (1979). Elevated plasma β-thromboglobulin levels in multiple myeloma and in polycythaemia vera,”
  52. (2010). Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score,”
  53. (2010). Endothelial heterogeneity associated with regional athero-susceptibility and adaptation to disturbed blood flow in vivo,”
  54. (1998). F.R.RicklesandM.N.Levine,“Venousthromboembolismin malignancy and malignancy in venous thromboembolism,”
  55. (2002). Fluid shear- and timedependent modulation of molecular interactions between PMNs and colon carcinomas,”
  56. (2010). Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient
  57. (1977). G.H.SackJr.,J.Levin,andW.R.Bell,“Trousseau’s syndrome andothermanifestationsofchronicdisseminatedcoagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features,”
  58. (2010). G.K.Bertsias,J.E.Salmon,andD.T.Boumpas,“Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade,”
  59. (1856). Gesammalte Abhandlungen zur Wissenschaftlichen Medtzin,M e d i n g e rS o h n ,F r a n k f u r t ,
  60. (2007). Gradl et al., “Value of contrast-enhanced ultrasound and elastography in imaging of prostate cancer,”
  61. (1998). h i g e m o r i ,H .W a d a ,K .M a t s u m o t o ,H .S h i k u
  62. (2002). h i n ,a n dA .D .B l a n n ,“ C a n c e ra n dt h e prothrombotic state,”
  63. (1966). h o m e t ,J .L a P o r t e ,a n dE .A .M c G r e w ,“ A t y p i c a lm o n o -cytes inpatientswithmalignanttumors,”ActaCytologica,v ol.
  64. (1990). Haemostatic abnormalitiesand outcome in patients with operable breast cancer,”
  65. (1987). Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications,”Journal of Clinical Oncology,
  66. (1988). Hemostatic effects ofhormonalstimulationin patients with metastatic prostate cancer,”
  67. (2010). High platelet count associatedwithvenousthromboembolismincancerpatients: results from the Vienna Cancer and Thrombosis Study
  68. (1986). Hypercoagulable state induced by cytostatic drugs in Stage II breast cancer patients,”
  69. (1993). Hypercoagulable states,”
  70. (1996). In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease,”
  71. (2010). Incidence of arterial cardiovascular events after venous thromboembolism: a systemic review and a metaanalysis,”
  72. (2006). Incidence of venousthrombosisinalargecohortof66329cancerpatients: results of a record linkage study,”
  73. (2010). Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy,” Thrombosis and Haemostasis,v o l .
  74. (1984). Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients,”Cancer,v o l .
  75. (1993). Increased plasmathrombomodulinincancerpatients,”Thrombosisand Haemostasis,
  76. (2007). Inhibition of platelet function: does it offer a chance of better cancer progression control?”
  77. (2010). J.Baran,M.Baj-Krzyworzeka,K.Weglarczyketal.,“Circulating tumour-derived microvesicles in plasma of gastric cancer patients,”
  78. (1993). Kraus et al.,“Activation ofcoagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis,”
  79. (1999). L w a l e e d ,M .C h i s h o l m ,a n dJ .L .F r a n c i s ,“ T h e significance of measuring monocyte tissue factor activity in patients with breast and colorectal cancer,”
  80. (2010). Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy,”
  81. (1977). Levin,andW .R.Bell,“T r ousseau ’ ssyndr ome andothermanifestationsofchronicdisseminatedcoagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features,”
  82. (1987). Louis,“Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines,”
  83. (2003). Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolismin patientswith cancer,”
  84. (2003). M.N.Levine,A.Y.Lee,andA.K.Kakkar,“FromTrousseauto targetedtherapy:newinsightsandinnovationsinthrombosis and cancer,”
  85. (2004). Management of thrombosis in cancer: primary prevention and secondary prophylaxis,”
  86. (2006). Mechanisms of cancer-induced thrombosis,”
  87. (2009). Microparticle-associated tissue factor activity in cancer patients with and without thrombosis,”
  88. (2009). Microparticles and arterial disease,”
  89. (2008). Microparticles and cancer,”
  90. (2003). Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer,”
  91. (1993). Monocytes and macrophages in cancer immunotherapy,”
  92. (1993). Myocardial infarction in young patients with Hodgkin’s disease—potential pathogenic role of radiotherapy, chemotherapy, and splenectomy,”
  93. (2010). n o w l s o n ,S .B a c c h u ,S .P a n e e s h a ,A .M c M a n u s
  94. NationalInstitute forHealth andClinical Excellence (NICE), “Venousthromboembolism:reducing therisk,”Guideline92;
  95. (2010). Normal ranges of angiogenesis regulatory proteins in human platelets,”
  96. (1988). o r g a n ,R .L .E d w a r d s ,a n dF .R .R i c k l e s ,“ M o n o c y t e procoagulant activity as a peripheral marker of clotting activation in cancer patients,” Haemostasis,v o l .1 8 ,n o .1 ,p p .
  97. (1993). O.Witherow,andM.E.Snell, “Coagulopathy in the prostate cancer patient: prevalence and clinical relevance,”
  98. (2010). O’Donnell et al., “Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery,”
  99. (2004). Organization, “Annex Table 2: deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002,” The world health report 2004— changing history,
  100. Phlegmasia alba dolens,”Clinique Medicale de l’Hotel Dieu de Paris,
  101. (1980). Plasma concentrations of the platelet-specific β-thromboglobulin in malignant disease,”
  102. (1991). Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer,”JournalofCancerResearchandClinical Oncology,v ol.
  103. (1991). Plasma thrombosis-inducing activity in 120 patients with primary lung cancer,”
  104. (1984). Platelet activation in patients with benign and malignant ovarian diseases,”
  105. (1988). Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation,”
  106. (2004). Platelet microparticles induce angiogenesis in vitro,”
  107. (2008). Platelet-derived microparticles and coagulation activation in breast cancer patients,” Thrombosis and Haemostasis,
  108. (2009). Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production,”
  109. (2004). Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis,”
  110. (1992). Platelets and cancer metastasis: a causal relationship?”
  111. (1980). Platelets as a source of growth-promoting factor(s) for tumor cells,”
  112. (1988). Platelets in tumor metastasis: generation of adenosine diphosphate by tumor cells is specific but unrelated to metastatic potential,”
  113. (1984). Potential role of platelets in the pathogenesis of tumor metastasis,”Blood,
  114. (1993). Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand Factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status,”
  115. (2000). Prognosis of cancers associated with venous thromboembolism,”
  116. (1992). R i c k l e s ,M .L e v i n e ,a n dR .L .E d w a r d s ,“ H e m o -static alterations in cancer patients,” Cancer and Metastasis Reviews,
  117. (2005). Randomized comparison of low molecular weight heparin and coumarin derivatives onthesurvivalofpatientswithcancerandvenous thromboembolism,”
  118. (1992). Reassessing the hemostatic disorder associated with acute promyelocytic leukemia,”
  119. (1979). Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracilinpatientswithhepaticmetastasesfromcolorectal cancer: a central oncology group study,”
  120. (2005). Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study,”
  121. (1984). Role of plasma,platelets, and endothelial cells in tumor metastasis,”
  122. (2006). Role of tissue factor in hemostasis and thrombosis,”
  123. (1979). S c i a l l a ,S .F .S p e c k a r t ,M .J .H a u t ,a n dD .B .K i m b a l l , “Alterations in platelet surface sialyltransferase activity and platelet aggregation in a group of cancer patients with a high incidence of thrombosis,”
  124. (2009). Shai,“Roleofplatelet-derived microparticles in angiogenesis and tumor progression,”
  125. (1986). Shortened platelet half-life in multiple myeloma,”
  126. (1997). Spontaneous arterial thrombosis with an advanced ovarian malignancy,”
  127. (1990). Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy,”
  128. (1980). Testing the monocyte-macrophage system in human cancer,”
  129. (2005). The activity of cancer procoagulant in cases of uterine leiomyomas,”
  130. (2001). The biology and tumour-related properties ofmonocytetissuefactor,”
  131. (2007). The effect of low molecular weight heparin on cancer survival. A systematic review and meta-analysis of randomised trials,”
  132. (1994). The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions,”
  133. (2007). The NCCN clinical practice guidelines on venous thromboembolic disease: strategies for improving VTE prophylaxis in hospitalized cancer patients,”
  134. (1978). The platelet-derived growth factor,”
  135. (2010). The relationship among acute-phase response proteins, cytokines and hormonesincachectic patientswithcoloncancer,”WorldJournal of Surgical Oncology,
  136. (2005). The risk of a second cancer after hospitalisation for venous thromboembolism,”
  137. (2003). The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients,”
  138. (2008). The role of platelet activation in tumor metastasis,” Expert Review of Anticancer Therapy,v o l .8 ,n o .8 ,p p .
  139. (1988). The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer,”TheNew
  140. (2009). Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from
  141. (2007). Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy,”
  142. (1987). Thrombosis and cancer,” Human Pathology,
  143. (2011). Thrombosis risk and survival in cancer patients with elevated C-reactive protein,”
  144. (1992). Thrombospondin as a mediator of cancer cell adhesion
  145. (2007). Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2,”
  146. (2000). Tissue concentration of plateletderived endothelial cell growth factor in colorectal cancer,”
  147. (2008). Tissue factor and cancer,”
  148. (2000). Tissue factor expression and angiogenesis in human prostate carcinoma,”Human Pathology,
  149. (1998). Tissue factor expression by monocytes: regulation and pathophysiological roles,”
  150. (1995). Tissue factor expression correlates with histological grade in human pancreatic cancer,”
  151. (1987). Tissue factor-dependent activation of platelets by cells and microvesicles of SK-OS-10 humanosteogenicsarcomacellline,”Invasionand
  152. (2007). Tissue factorpositive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer,” Thrombosis and Haemostasis,
  153. (1998). Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis,”
  154. (1993). Tumor cell procoagulant and urokinase expression in carcinoma of the ovary,”
  155. (2009). Tumorderived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy,”Clinical
  156. (1987). Tumour-cell-induced platelet aggregation: studies with cloned metastaticand nonmetastaticvariants,”Invasion and Metastasis,v ol.7,no .5,p p .
  157. (1991). Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer,”
  158. Venous thromboembolic events and organspecificoccultcancers:areviewandmeta-analysis,”Journal of Thrombosis and Haemostasis,
  159. (1997). Venous thromboembolism and cancer: a twoway clinical association,”
  160. (2010). Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis,”
  161. (2009). Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action,”JournalofClinicalOncology,vol.27,no.29,pp.4919– 4926,
  162. (2002). Venousthrombosisin patients with solid tumors: determination of frequency and characteristics,”
  163. (2001). Virchow’s triad revisited: the importance of soluble coagulation factors, the endothelium, and platelets,”
  164. (2003). Von Tempelhoff,L .H e i l m a n n ,G .H o m m e l ,a n dK . Pollow, “Impact of rheological variables
  165. (2008). Vormittaget al., “High plasma levels of solubleP-selectin arepredictive ofvenousthromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study
  166. (1995). Williamson,“Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor,” Lancet,v o l .
  167. (2005). Wojtukiewicz et al.,“Cancerprocoagulantinpatientswithadenocarcinomas,”
  168. (2010). X.Zhou,S.Teegala,A.Huen etal.,“Incidenceandriskfactors of venous thromboembolic events in lymphoma,”
  169. (1995). Zeff,E .L e e ,a n dR .D .B o n a , “Tissue factor expression in human leukocytes and tumor cells,” Thrombosis and Haemostasis,